生物标记合作与授权协议：2016-2025

本报告全面深入分析了全球领先的生物製药公司签署的生物标记协议，并提供前所未有的资讯取得管道。

本报告详细阐述并分析了公司签署生物标记协议的原因和方法。这些协议通常包含多个组成部分，从合作研发开始，最终实现成果的商业化。

本报告涵盖合作研发、研究和授权协议。

本报告包​​含自2016年以来公布的545项生物标誌物交易的完整清单，其中包括可用的财务条款以及指向各方披露的实际生物标誌物合作交易在线记录的链接。此外，在条件允许的情况下，记录中还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

主要优势：

• 了解自 2016 年以来的合约趋势
• 查看生物标记领域的合作和授权协议
• 基准分析：确定交易市场价值
• 财务条款：预付款、里程碑付款、特许权使用费
• 依公司名称（A-Z）、合约类型和治疗领域分类的合约目录
• 以价值排名的主要交易
• 最活跃的交易撮合者
• 识别每份合约的资产描述和条款
• 存取合约文件：深入了解合约结构
• 尽职调查：评估拟议合约条款是否适合您的合作伙伴
• 节省数百小时的研究时间

分析合约内容有助于进行以下方面的尽职调查：

• 合约授予或选择哪些具体权利？
• 合约实际上赋予合作伙伴哪些权利？
• 授予了哪些独家经营权？
• 合约的付款结构是怎样的？
• 销售和付款将如何审计？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 智慧财产权（IPR）将如何处理，所有权归谁？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果所有权发生变更，会发生什么事？
• 双方约定的转授权和分包条款是什么？
• 公司通常会包含哪些标准条款？
• 根据交易对手和合约类型，有哪些标准条款会有所不同？
• 根据合约法，公司要求适用哪个司法管辖区（法院）的法律？

目录

摘要整理

第一章：引言

第二章：生物标记合约趋势

• 过去几年生物标记合约数量
• 最活跃的承包商
• 依合约类型划分的生物标记合约
• 依治疗领域划分的生物标记合约
• 依行业划分的生物标记合约
• 生物标誌物合约条款

第三章：主要生物标记合约

• 以合约金额划分的主要生物标记合约

第四章：最活跃的生物标记承包商

• 最活跃的生物标记承包商承包商
• 最活跃的生物标记承包商简介

第五章：生物标记合约交易目录

• 生物标誌合约交易目录

第六章：依技术类型划分的生物标记合约

• 合约目录
• 依公司（A-Z）划分的合约目录
• 依合约类型划分的合约目录
• 依治疗领域划分的合约目录
• 合约类型定义
• 关于 Biopharma Research Ltd
• 当前合作伙伴
• 当前协议
• 来自目前合作伙伴的最新报告标题

Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of biomarker deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter biomarker deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 545 biomarker deals announced since 2016 including financial terms where available including links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of biomarker dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in biomarker dealmaking since 2016.

Chapter 3 provides an overview of the leading biomarker deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in biomarker dealmaking with a brief summary followed by a comprehensive listing of biomarker deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of biomarker deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since Jan 2016. The chapter is organized by specific biomarker technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in biomarker deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Biomarker Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse biomarker collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Biomarker Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of biomarker trends and structure of deals entered into by leading biopharma companies worldwide.

Biomarker Collaboration and Licensing Deals includes:

• Trends in biomarker dealmaking in the biopharma industry
• Directory of biomarker deal records covering pharmaceutical and biotechnology
• The leading biomarker deals by value
• Most active biomarker licensing dealmakers
• Biomarker Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in biomarker dealmaking

• 2.1. Introduction
• 2.2. Biomarker deals over the years
• 2.3. Most active biomarker dealmakers
• 2.4. Biomarker deals by deal type
• 2.5. Biomarker deals by therapy area
• 2.6. Biomarker deals by industry sector
• 2.7. Deal terms for biomarker deals
  • 2.7.1 Biomarker deals headline values
  • 2.7.2 Biomarker deal upfront payments
  • 2.7.3 Biomarker deal milestone payments
  • 2.7.4 Biomarker royalty rates

Chapter 3 - Leading biomarker deals

• 3.1. Introduction
• 3.2. Top biomarker deals by value

Chapter 4 - Most active biomarker dealmakers

• 4.1. Introduction
• 4.2. Most active biomarker dealmakers
• 4.3. Most active biomarker deals company profiles

Chapter 5 - Biomarker contracts dealmaking directory

• 5.1. Introduction
• 5.2. Biomarker contracts dealmaking directory

Chapter 6 - Biomarker dealmaking by technology type

• Deal directory
• Deal directory - Biomarker deals by company A-Z
• Deal directory - Biomarker deals by deal type
• Deal directory - Biomarker deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Biomarker deals since 2016
• Figure 2: Active biomarker dealmaking activity - 2016 - 2025
• Figure 3: Biomarker deals by deal type since 2016
• Figure 4: Biomarker deals by therapy area since 2016
• Figure 5: Biomarker deals by industry sector since 2016
• Figure 6: Biomarker deals with a headline value
• Figure 7: Biomarker deals with an upfront value
• Figure 8: Biomarker deals with a milestone value
• Figure 9: Biomarker deals with a royalty rate value
• Figure 10: Top biomarker deals by value since 2016
• Figure 11: Most active biomarker dealmakers 2016 - 2025
• Figure 12: Biomarker deals by technology type since 2016